Floatz logo

Therapeutic 4Scar19 Cells

B-Cell Leukemia

Zhujiang HospitalCell therapyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

141 Active assets in the B-Cell Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Therapeutic 4Scar19 Cells is also rated in:

B-cell acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
B-cell neoplasmDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →